June 01, 2017

Evolva in contract negotiations with the US government for funding to advance nootkatone against Zika

Evolva (SIX: EVE) confirms a media report stating that the Company is negotiating a sole-source contract with the US Biomedical Advanced Research and Development Authority (BARDA) to advance the development and EPA registration of Evolva’s nootkatone product to help in the fight against the mosquitoes that transmit Zika virus. No further details can be provided at this time.
PDF Download

read more »

May 16, 2017

Synaffix Secures End-to-End Patent Protection of Its ADC Technology Platform as Its HydraSpace™ Patent Grants in the United States

Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology platforms, today announced that a key patent covering its HydraSpace™ spacer technology has been granted by the United States Patent and Trademark Office (US 9,636,421 B2).
PDF Download

read more »

May 03, 2017

UroGen Pharma Announces Pricing of Initial Public Offering

UroGen Pharma Ltd., a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, announced today the pricing of its initial public offering of 4,473,373 ordinary shares at a public offering price of $13.00 per share for aggregate gross proceeds of approximately $58.2 million. The shares are scheduled to begin trading on The NASDAQ Global Market on May 4, 2017 under the ticker symbol "URGN." In addition, UroGen Pharma granted the underwriters a 30-day option to purchase up to an additional 671,005 ordinary shares. The offering is expected to close on or about May 9, 2017, subject to customary closing conditions.
PDF Download

read more »

April 03, 2017

Evolva announces long-term commercial agreement with Cargill

EverSweetTM next-generation stevia ingredient on track for 2018 launch

Evolva (SIX: EVE) announced today that it has entered a major collaboration agreement with Cargill for the production and commercialisation of EverSweetTM, the next-generation stevia sweetener.This product is on track for a 2018 launch, securing its first-mover advantage.
PDF Download - English Version
PDF Download - German Version



 

Evolva (SIX: EVE) announced today that it has entered a major collaboration agreement with Cargill for the production and commercialisation of EverSweetTM, the next-generation stevia sweetener. This product is on track for a 2018 launch, securing its first-mover advantage. - See more at: http://www.evolva.com/press-release/evolva-announces-long-term-commercial-agreement-with-cargill/#sthash.nb6PmIJw.dpuf
Evolva (SIX: EVE) announced today that it has entered a major collaboration agreement with Cargill for the production and commercialisation of EverSweetTM, the next-generation stevia sweetener. This product is on track for a 2018 launch, securing its first-mover advantage. - See more at: http://www.evolva.com/press-release/evolva-announces-long-term-commercial-agreement-with-cargill/#sthash.nb6PmIJw.dpuf
Evolva (SIX: EVE) announced today that it has entered a major collaboration agreement with Cargill for the production and commercialisation of EverSweetTM, the next-generation stevia sweetener. This product is on track for a 2018 launch, securing its first-mover advantage. - See more at: http://www.evolva.com/press-release/evolva-announces-long-term-commercial-agreement-with-cargill/#sthash.XkBKDeqO.dpuf

read more »

March 30, 2017

Symetis and Boston Scientific reach USD 435 million purchase agreement

Symetis, a medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions, today announced that it has agreed to be acquired by Boston Scientific for $435 million in an all cash, up-front payment.
PDF Download

read more »

March 09, 2017

Evolva achieves second milestone in fragrance & flavour alliance with Takasago

Evolva (SIX: EVE) today announces reaching the second technical milestone under the multi-year R&D alliance with Takasago. This achievement brings the project closer to the launch of the target ingredients and prompts a total milestone payment of USD 1 million to Evolva as well as the continuation of the collaboration into the next phases.
PDF Download - English version
PDF Download - German version
 

read more »

February 20, 2017

New Data Demonstrate that Synaffix ADCs Significantly Expand the Therapeutic Index vs Cysteine-Engineered ADCs

Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology, today announced a new set of head-to-head data, that demonstrates the potential of its technology to significantly expand the therapeutic index vs cysteine-engineered ADCs.
PDF Download

read more »

January 17, 2017

Bird Rock Bio Receives Approval to Start First in Human Clinical Trial for Namacizumab, Enters Into Agreement with GE Healthcare for Process Development and Scale-up to Provide Clinical Phase 2 cGMP Material

and enters into a Collaboration and Option Agreement with Janssen Pharmaceuticals, Inc.

Bird Rock Bio, Inc., a clinical stage biopharmaceutical company, announced today that it has received approval for the initiation of a two-part Phase 1 clinical trial for namacizumab, a novel therapeutic antibody to the cannabinoid 1 receptor (CB1). In addition, Bird Rock Bio has entered into an agreement with GE Healthcare for process development, formulation, and manufacture of namacizumab in preparation for Phase 2 studies. Furthermore, the Phase 1 trial, process development, and Phase 2 preparation will be funded under a collaboration and option agreement with Janssen Pharmaceuticals, Inc.
PDF Download

read more »